Pioglitazone promotes peripheral nerve remyelination after crush injury through CD36 upregulation

Journal of the Peripheral Nervous System

Volumn 13, Issue 3, 2008, Pages 242-248

  Eto, Masaki ^a   Sumi, Hisae ^a   Fujimura, Harutoshi ^b   Yoshikawa, Hiroo ^c   Sakoda, Saburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TONEYAMA NATIONAL HOSPITAL   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

C57Bl 6; Macrophage; RCA 1; Scavenger receptor; Thiazolidinedione

Indexed keywords

CD36 ANTIGEN; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DRUG EFFECT; HISTOCHEMISTRY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOUSE; NERVE CRUSH; NERVE FIBER DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REMYELINIZATION;

ANIMALS; ANTIGENS, CD36; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MYELIN SHEATH; NERVE CRUSH; NEUROPROTECTIVE AGENTS; SCIATIC NERVE; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 52949113454     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2008.00183.x     Document Type: Article

References (27)

1. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA (1993). Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem 268 : 17665 17668.
2. Asch AS, Barnwell J, Silverstein RL, Nachman RL (1987). Isolation of the thrombospondin membrane receptor. J Clin Invest 79 : 1054 1061.
3. Bodles AM, Varma V, Yao-Borengasser A, Phanavanh B, Peterson CA, McGehee RE Jr., Rasouli N, Wabitsch M, Kern PA (2006). Pioglitazone induces apoptosis of macrophages in human adipose tissue. J Lipid Res 47 : 2080 2088.
4. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ (2000). The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164 : 1364 1371.
5. Eto M, Yoshikawa H, Fujimura H, Naba I, Sumi-Akamaru H, Takayasu S, Itabe H, Sakoda S (2003). The role of CD36 in peripheral nerve remyelination after crush injury. Eur J Neurosci 17 : 2659 2666.
6. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT (2002). Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 51 : 694 702.
7. Hirakata M, Tozawa R, Imura Y, Sugiyama Y (2004). Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem Biophys Res Commun 323 : 782 788.
8. Jiang C, Ting AT, Seed B (1998). PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 : 82 86.
9. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI (1998). Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128 : 176 185.
10. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ (2002). Metabolic and additional vascular effects of thiazolidinediones. Drugs 62 : 1463 1480.
11. McCarty MF, Barroso-Aranda J, Contreras F (2008). PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation. Med Hypotheses 70 : 419 423.
12. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N (1998). Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 273 : 16710 16714.
13. Murphy FJ, Reen DJ (1996). Differential expression of function-related antigens on newborn and adult monocyte subpopulations. Immunology 89 : 587 591.
14. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, Nakata A, Ishigami M, Miyagawa J, Kameda-Takemura K (1995). Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 96 : 1859 1865.
15. Patel J, Anderson RJ, Rappaport EB (1999). Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1 : 165 172.
16. Pershadsingh HA, Heneka MT, Saini R, Amin NM, Broeske DJ, Feinstein DL (2004). Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation 1 : 3.
17. Qi N, Kazdova L, Zidek V, Landa V, Kren V, Pershadsingh HA, Lezin ES, Abumrad NA, Pravenec M, Kurtz TW (2002). Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone. J Biol Chem 277 : 48501 48507.
18. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998). The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 : 79 82.
19. Rigotti A, Acton SL, Krieger M (1995). The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 270 : 16221 16224.
20. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE (2001). The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 12 : 413 423.
21. Ryeom SW, Silverstein RL, Scotto A, Sparrow JR (1996). Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36. J Biol Chem 271 : 20536 20539.
22. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT (2004). Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol 75 : 478 485.
23. Talle MA, Rao PE, Westberg E, Allegar N, Makowski M, Mittler RS, Goldstein G (1983). Patterns of antigenic expression on human monocytes as defined by monoclonal antibodies. Cell Immunol 78 : 83 99.
24. Tandon NN, Kralisz U, Jamieson GA (1989). Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem 264 : 7576 7583.
25. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998). PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 : 241 252.
26. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, Henry RR (2003). Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab 285 : E354 E362.
27. Yamaguchi A, Yamamoto N, Akamatsu N, Saido TC, Kaneda M, Umeda M, Tanoue K (2000). PS-liposome and ox-LDL bind to different sites of the immunodominant domain (#155-183) of CD36: a study with GS95, a new anti-CD36 monoclonal antibody. Thromb Res 97 : 317 326.